vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Sabre Corp (SABR). Click either name above to swap in a different company.

Sabre Corp is the larger business by last-quarter revenue ($760.3M vs $321.1M, roughly 2.4× MADRIGAL PHARMACEUTICALS, INC.). Sabre Corp runs the higher net margin — 1.1% vs -18.2%, a 19.3% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 8.3%). MADRIGAL PHARMACEUTICALS, INC. produced more free cash flow last quarter ($-133.8M vs $-155.4M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Sabre Corporation, a travel technology company headquartered in Southlake, Texas, is the largest global distribution systems (GDS) provider for air bookings. The company's primary product, the Sabre Global Distribution System, and others like it, act as neutral intermediaries, connecting travel suppliers like airlines and hotels with travel sellers like agencies. They offer real-time availability and pricing, making them important for corporate travel management.

MDGL vs SABR — Head-to-Head

Bigger by revenue
SABR
SABR
2.4× larger
SABR
$760.3M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+202.5% gap
MDGL
210.8%
8.3%
SABR
Higher net margin
SABR
SABR
19.3% more per $
SABR
1.1%
-18.2%
MDGL
More free cash flow
MDGL
MDGL
$21.5M more FCF
MDGL
$-133.8M
$-155.4M
SABR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MDGL
MDGL
SABR
SABR
Revenue
$321.1M
$760.3M
Net Profit
$-58.6M
$8.1M
Gross Margin
Operating Margin
-18.6%
15.2%
Net Margin
-18.2%
1.1%
Revenue YoY
210.8%
8.3%
Net Profit YoY
1.4%
-77.0%
EPS (diluted)
$-2.55
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
SABR
SABR
Q1 26
$760.3M
Q4 25
$321.1M
$592.0M
Q3 25
$287.3M
$715.2M
Q2 25
$212.8M
$687.1M
Q1 25
$137.3M
$776.6M
Q4 24
$103.3M
$575.6M
Q3 24
$62.2M
$691.3M
Q2 24
$695.0M
Net Profit
MDGL
MDGL
SABR
SABR
Q1 26
$8.1M
Q4 25
$-58.6M
$-103.5M
Q3 25
$-114.2M
$848.5M
Q2 25
$-42.3M
$-256.5M
Q1 25
$-73.2M
$35.5M
Q4 24
$-59.4M
$-74.7M
Q3 24
$-107.0M
$-62.8M
Q2 24
$-69.8M
Gross Margin
MDGL
MDGL
SABR
SABR
Q1 26
Q4 25
55.4%
Q3 25
56.2%
Q2 25
56.9%
Q1 25
96.7%
57.0%
Q4 24
58.8%
Q3 24
57.4%
Q2 24
57.8%
Operating Margin
MDGL
MDGL
SABR
SABR
Q1 26
15.2%
Q4 25
-18.6%
1.6%
Q3 25
-39.7%
13.1%
Q2 25
-22.2%
13.0%
Q1 25
-57.8%
13.3%
Q4 24
-64.8%
6.5%
Q3 24
-187.1%
8.4%
Q2 24
7.0%
Net Margin
MDGL
MDGL
SABR
SABR
Q1 26
1.1%
Q4 25
-18.2%
-17.5%
Q3 25
-39.8%
118.6%
Q2 25
-19.9%
-37.3%
Q1 25
-53.4%
4.6%
Q4 24
-57.5%
-13.0%
Q3 24
-172.0%
-9.1%
Q2 24
-10.0%
EPS (diluted)
MDGL
MDGL
SABR
SABR
Q1 26
$0.02
Q4 25
$-2.55
$-0.08
Q3 25
$-5.08
$1.98
Q2 25
$-1.90
$-0.65
Q1 25
$-3.32
$0.09
Q4 24
$-2.50
$-0.20
Q3 24
$-4.92
$-0.16
Q2 24
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
SABR
SABR
Cash + ST InvestmentsLiquidity on hand
$198.7M
$643.6M
Total DebtLower is stronger
$339.9M
$4.3B
Stockholders' EquityBook value
$602.7M
Total Assets
$1.3B
$4.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
SABR
SABR
Q1 26
$643.6M
Q4 25
$198.7M
$791.6M
Q3 25
$295.7M
$661.7M
Q2 25
$186.2M
$426.1M
Q1 25
$183.6M
$651.1M
Q4 24
$100.0M
$724.5M
Q3 24
$232.7M
$668.8M
Q2 24
$612.6M
Total Debt
MDGL
MDGL
SABR
SABR
Q1 26
$4.3B
Q4 25
$339.9M
$4.3B
Q3 25
$339.8M
$4.2B
Q2 25
$118.4M
$5.1B
Q1 25
$118.0M
$5.0B
Q4 24
$117.6M
$5.0B
Q3 24
$117.1M
$4.9B
Q2 24
$4.9B
Stockholders' Equity
MDGL
MDGL
SABR
SABR
Q1 26
Q4 25
$602.7M
$-1.0B
Q3 25
$625.7M
$-950.8M
Q2 25
$696.0M
$-1.8B
Q1 25
$710.6M
$-1.6B
Q4 24
$754.4M
$-1.6B
Q3 24
$777.2M
$-1.5B
Q2 24
$-1.5B
Total Assets
MDGL
MDGL
SABR
SABR
Q1 26
$4.3B
Q4 25
$1.3B
$4.5B
Q3 25
$1.4B
$4.4B
Q2 25
$1.0B
$4.4B
Q1 25
$996.6M
$4.7B
Q4 24
$1.0B
$4.6B
Q3 24
$1.1B
$4.7B
Q2 24
$4.7B
Debt / Equity
MDGL
MDGL
SABR
SABR
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
SABR
SABR
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
$-155.4M
FCF MarginFCF / Revenue
-41.7%
-20.4%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
SABR
SABR
Q1 26
Q4 25
$-133.5M
Q3 25
$79.8M
$33.7M
Q2 25
$-47.1M
Q1 25
$-88.9M
$-80.6M
Q4 24
$-104.5M
$75.7M
Q3 24
$-67.0M
$24.4M
Q2 24
$38.2M
Free Cash Flow
MDGL
MDGL
SABR
SABR
Q1 26
$-155.4M
Q4 25
$-133.8M
Q3 25
$79.0M
$13.4M
Q2 25
Q1 25
$-98.5M
Q4 24
$-104.7M
$61.0M
Q3 24
$-67.8M
$5.1M
Q2 24
$20.4M
FCF Margin
MDGL
MDGL
SABR
SABR
Q1 26
-20.4%
Q4 25
-41.7%
Q3 25
27.5%
1.9%
Q2 25
Q1 25
-12.7%
Q4 24
-101.3%
10.6%
Q3 24
-109.0%
0.7%
Q2 24
2.9%
Capex Intensity
MDGL
MDGL
SABR
SABR
Q1 26
Q4 25
0.1%
4.0%
Q3 25
0.3%
2.8%
Q2 25
0.0%
3.1%
Q1 25
0.0%
2.3%
Q4 24
0.2%
2.6%
Q3 24
1.3%
2.8%
Q2 24
2.6%
Cash Conversion
MDGL
MDGL
SABR
SABR
Q1 26
Q4 25
Q3 25
0.04×
Q2 25
Q1 25
-2.27×
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

SABR
SABR

Marketplace$618.0M81%
Airline Technology$142.0M19%

Related Comparisons